Items Tagged ‘CheckMate -066 trial’

December 2nd, 2015

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma

By

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The indication for this expanded approval specifies that Opdivo can be used for treatment […]

View full entry

Tags: advanced, CheckMate -066 trial, Melanoma, metastatic, News, opdivo, Skin Cancer, Stage III Melanoma, Stage IV Melanoma